In the Finnish breast and ovarian cancer families six BRCA1 and five BRCA2 mutations have been found recurrently. Some of these recurrent mutations have also been seen elsewhere in the world, while others are exclusively of Finnish origin. A haplotype analysis of 26 Finnish families carrying a BRCA1 mutation and 20 families with a BRCA2 mutation indicated that the carriers of each recurrent mutation have common ancestors. The common ancestors were estimated to trace back to 7-36 generations (150-800 years). The time estimates and the geographical clustering of these founder mutations in Finland are in concordance with the population history of this country. Analysis of the cancer phenotypes showed differential ovarian cancer expression in families carrying mutations in the 5' and 3' ends of the BRCA1 gene, and earlier age of ovarian cancer onset in families with BRCA1 mutations compared with families with BRCA2 mutations. The identification of prominent and regional BRCA1 and BRCA2 founder mutations in Finland will have significant impact on diagnostics in Finnish breast and ovarian cancer families. An isolated population with known history and multiple local founder effects in multigenic disease may offer distinct advantages also for mapping novel predisposing genes.
Introduction
The cloning of BRCA1 1 and BRCA2, 2 the major known genes predisposing to early-onset breast cancer and ovarian cancer, has resulted in rapid identification of a large number of families with mutations in these genes. 3 Although both genes exhibit numerous distinct mutations, several alterations have been found recurrently in defined ethnic and geographic populations, especially in the Ashkenazim and in Iceland. [4] [5] [6] In Finland, 11 distinct BRCA1 and seven BRCA2 mutations have been detected, [7] [8] [9] and six of the BRCA1 and five of the BRCA2 mutations are recurrent. Some of these mutations are unique to Finland, while others have also been reported elsewhere in the world, like BRCA2 999del5, a strong founder mutation in Iceland as well. 4, 6 We have here investigated the mutation-associated haplotype conservation in Finnish BRCA1 and BRCA2 families. We have estimated the time since the common ancestor for the families segregating the same mutation and also studied the geographical distribution of the alterations in Finland. In addition, the breast and ovarian cancer phenotypes of the families were analysed.
Material and methods

Families studied
Altogether 26 Finnish breast or breast-ovarian cancer families carrying recurrent BRCA1 mutations and 20 families with BRCA2 mutations were studied for haplotype conservation, and 34 BRCA1 and 37 BRCA2 families for the cancer phenotype. The families had previously been ascertained and mutations identified [7] [8] [9] in four University Hospitals in Finland (Helsinki, Oulu, Tampere, and Kuopio, additional unpublished data). The permission for the genetic analysis was obtained by written informed consent. The family data were collected by interviewing the index patients as well as by searching church parish records and population registry data. Cancer diagnoses and ages at onset were obtained from hospital records, death certificates or family questionnaires. The diagnoses were confirmed through the Finnish Cancer Registry whenever possible. The study was approved by ethical committees of the hospitals and appropriate permissions were obtained from the Ministry of Social Affairs and Health in Finland. For comparison of the mutation-associated haplotypes of the BRCA1 3744delT mutation in Finland and Sweden, 10 samples from four Swedish families were also included.
Mutations studied
The BRCA1 and BRCA2 mutations identified in Finland and the recurrent BRCA1 and BRCA2 mutations studied in the haplotype analysis are indicated in Table 1 . Mutation-specific breast and ovarian cancer phenotypes are also shown in Table 1 . Figure 1 ). Primer sequences for markers D13S260 through D13S267 were positioned and marker order and physical distances were determined using Sequencher v3.0 (Gene Codes Corporation, Ann Arbor, MI, USA) and the genomic sequence 19 for this region. Physical distances for markers D13S260 through D13S267 were converted to centiMorgans assuming 1 cM = 0.5 Mb, which was the average observed ratio at this region. For 17q21 markers PCR products were labelled with [α-
32 P]-dCTP and separated by denaturing polyacrylamide gel (7%) electrophoresis. Biomax X-ray films (Kodak, NY, NY, USA) were used for autoradiography. Allele sizes were determined using M13mp18 marker (Sequenase Kit, USB, Cleveland, OH, USA). For 13q12 markers forward PCR primers were fluorescent dye labelled with either FAM, HEX or TET (PE Applied Biosystems, Foster City, CA, USA). The amplification products were separated on an ABI 377 instrument (PE Applied Biosystems), and genotype data were analysed using GeneScan 3.1 and Genotyper 2.0 software from PE Applied Biosystems. Allele sizes were matched according to the genotype of CEPH reference individual 134702 (PE Applied Biosystems).
In order to define the allele frequencies in the Finnish population, 42 and 96 healthy individuals were genotyped for chromosome 17q21 and 13q12 markers, respectively.
Haplotyping and estimation of the time since common ancestors (spreading of the mutations)
The haplotypes were constructed by Genehunter program and/or manually. Historical recombinations were reconstructed assuming minimal parsimony. Starting from the site of the mutation and moving outwards in both directions, historical recombinations were noted as the branching of the haplotype when two or more different alleles were observed for a marker. Examples of such recombinational histories for the BRCA1 3744delT and BRCA2 9346nt-2A ® G chromosomes are depicted in Figure 1 .
The number of generations (g) since the common ancestor of the families studied, denoted in the following as the time since spreading of the mutation, was estimated by the LuriaDelbrück equation 20 of p excess = α(1-θ) g , where α = 1 (all chromosomes carry the same mutation), θ refers to the recombination fraction between the mutation and marker locus, and p excess = (p affected -p normal )/(1 -p normal ), where p affected = fraction of the ancestral chromosomes (allele) of all affected chromosomes and p normal = frequency of the same allele in normal population chromosomes. The average of the estimations was considered as the most likely time since the common ancestor. Alternatively, a modification was applied where p excess value for each marker was the minimum and maximum fraction of chromosomes carrying the most common shared allele for that marker based on the branched haplotype tree.
Phenotype analysis
Thirty-four families with a BRCA1 and 37 with a BRCA2 mutation were examined for breast and ovarian cancer phenotype. All cancer cases in the families were included in the phenotype study, with the exception of those who were known not to be BRCA1 or BRCA2 mutation carriers. end of the gene) and the breast and ovarian cancer phenotype in the BRCA1 families was analysed using Fisher's exact test. Only one of the BRCA2 mutations (6503delTT) is located in the ovarian cancer cluster region (OCCR), 21 which does not allow assessment of the genotype-phenotype correlation. The variation of the age at diagnosis was analysed for both genes and both phenotypes by unpaired t-test. Cumulative age-specific percentages of age at onset for breast and ovarian cancer using 5-year intervals were determined for the BRCA1 and BRCA2 families as well as the general population.
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Results and discussion
Haplotype analysis
The haplotype analysis showed that the carriers of each recurrent mutation have common ancestors. Variation in the length of the shared haplotype indicates that distinct mutations probably started to spread at different time periods, which is also supported by the geographical distribution of the mutations and their relationship to the population history and settlement of the country. The conserved core haplotypes as well as the time estimates and geographical distribution of the origins of the families are shown in Figure 2 . Both methods used for estimating the time since the spread of the mutations began gave consistent results. The estimates derived from using the population-based allele frequencies were within the range of minimum and maximum values derived from the modification using information from the branched haplotype tree. Recently, recombination suppression in a region of 200-400 kb including and immediately adjacent to BRCA1 has been reported. 23 The Luria-Delbrück calculation uses data from observed historically recombined chromosomes. The generation estimates are based on the average value of all recombined markers studied and the common haplotypes extended outside the suppression region. Thus the short suppressed region that does not recombine essentially looks like a 'point' in the genome and is expected to have little effect on the time estimates here. Interestingly, more extensive variation of the alleles was denoted in this study than reported by Liu and Barker. 23 Among the five different BRCA1 mutation haplotypes, four different alleles were present in the intragenic marker D17S855 within the reported recombination suppression region. The BRCA1 mutation 3744delT (haplotype reconstruction shown in Figure 1a ) was estimated to have started to spread 23-36 generations (500-700 years) ago. The alleles in the short conserved haplotype (1.6 cM) of the seven Finnish and four Swedish families analysed are rare (estimated haplotype frequency in the Finnish population 0.57%), supporting the common origin of the families. According to the church records, a majority of the Finnish families have lived in Central Ostrobothnia for at least 300 years, whereas the Swedish ones come from the opposite side of the Gulf of Bothnia. Thus, the mutation could have been brought across the sea from Sweden to Finland, along with Swedish settlers. 24 The origins of the families with the 4216nt-2A ® G mutation also cluster in Central Ostrobothnia and further in Central Finland inhabited after the fifteenth century, during the more permanent settlement of central and northern parts of the country. 24, 25 This mutation is unique to the Finns, and although it is the most frequent BRCA1 mutation in Finland, we estimated that the spread of this mutation started fairly recently (less than 10 generations ago). The 4446C ® T mutation is reported frequently in the Breast Cancer Information Core database (BIC), 3 and has been detected at least in Belgium, Canada, France, the UK and the USA. Several distinct disease-linked haplotypes segregating with this mutation indicate independent origins of the same mutation. [26] [27] [28] [29] In Finland, the three kindreds share a 7.9 cM core haplotype and the origins of the families cluster in a remote geographical location in Southern Karelia, near the Russian border. This particular mutation could be a distinct mutational event in Finland, supporting the hypothesis of a hotspot site. The 3604delA has also been reported several times in BIC, 3 and has previously been found in Belgium and the Netherlands. 30 The geographical location of all the families in the most southern and coastal part of Finland may suggest that the mutation originated from Central Europe. Besides Finland, 5370C ® T has been identified in Austria. 31 The BRCA2 mutation 9346nt-2A ® G (haplotype reconstruction shown in Figure 1b ) has been found in nine different families, and represents an alteration unique to the Finns. The spread of this mutation was estimated to have started 7-11 generations (150-200 years) ago. This is also supported by the distribution of the origins of the families in the northern and eastern parts of the country that were settled after the fifteenth century, followed by regional population expansions in the seventeenth century. 24 The 7708C ® T mutation, which is also unique to the Finns, seems to be of older origin (200-400 years) with dispersed geographical pattern both in the regions of older as well as more recent inhabitation. The 8555T ® G mutation is also unique to Finland, and all the families originate from Pirkanmaa. Although this part of the country was inhabited early in our population history, this mutation is not widespread but has remained as a regional founder mutation for 7-9 generations.
The geographical distribution of 6503delTT is quite similar to that of 9346nt-2A ® G as both mutations have spread into the late settlement area. 6503delTT has been listed several times in BIC 3 and families with this mutation have been reported in Belgium, the Netherlands, Sweden, the UK, and the USA. Phenotypic studies have suggested that BRCA1 mutations in families with a high proportion of ovarian cancer tend to be located at the 5' end, whilst families exhibiting predominantly breast cancer seem to have mutations at the 3' end of the gene. 34 A significant correlation between the location of the BRCA1 mutation and the cancer phenotype was also Altogether, phenotype information was available from 34 BRCA1 families and 37 BRCA2 families, and ovarian cancer was present in 74% and 43%, respectively ( Table 1) . The age at ovarian cancer onset was significantly earlier in the BRCA1 families (mean 51 years) than in the BRCA2 families (mean 61 years) (P < 0.0005, unpaired t-test), with almost 60% of the BRCA1 cases diagnosed before age 50 (Figure 3a) . However, the distribution of diagnostic ages for breast cancer was similar in the BRCA1 (mean 46 years) and BRCA2 (mean 48 years) families (Figure 3b ). Identification of larger number of individuals with these prevalent founder mutations in Finland will facilitate analysis of mutation-specific cancer risks and phenotypes. This will affect the clinical management of families carrying these mutations. Furthermore, environmental or other genetic factors modifying the cancer risks can ideally be studied in a genetically homogeneous population, especially in families carrying identical mutations. In Finland the 11 known recurrent BRCA1/2 mutations cover 84% of all BRCA1 and BRCA2 families found in screening the entire genes. [7] [8] [9] Whilst an unknown fraction, perhaps as high as almost 40% of mutations, may remain undetected by any mutation detection method, 35 linkage analysis in 24 of our large mutation-negative families suggested possible linkage to either BRCA1 or BRCA2 in only 4 (17%) (Kainu T et al, 2000, unpublished data). Thus, the major Finnish founder mutations may already have been identified. The high coverage of the founder mutations in Finland has also significant impact on diagnostics, which can first be based on direct screening of these mutations. Especially in some parts of the country, the mutation spectrum is very narrow and specific, whereas in the capital region of Helsinki, almost all Finnish mutations have been detected. Finally, the observation of multiple local founder effects in a multigenic disease provides support for the concept that an isolated population with known history may offer distinct advantages also for mapping novel predisposing genes. 
